Immatics NV (NASDAQ:IMTX) is Among the best German stocks to buy, according to analysts. On March 5, Immatics NV (NASDAQ:IMTX) reported its financial results for the year ended December 31. It also provided updates on its business.
Financially, the company reported revenue of $56.8 million in 2024, compared to revenue of $183.1 million. For the change in revenue, management explained that in 2024, there was a one-time non-cash revenue with the company’s agreement with Bristol-Myers Squibb.
Turning to the bottom line, the company posted a net loss of $230.8 million in 2025, compared to a net profit of $17.9 million in 2024.
In a business update, Immatics NV said a Phase 3 SUPRAME trial for its compound, called Enzo-Cell (IMA203), was ongoing, and that enrollment rates were strong. This trial is on the efficacy, safety, and tolerability of this drug candidate. Enzo cell therapy is for patients with certain types of melanoma. Immatics expects to begin final analyzes of study data in late 2026. It expects to receive marketing approval for the drug candidate in the first half of 2027 and then bring the product to market in the second half of 2027. The company has several other drug candidates in various stages.
Immatics NV ended the quarter with $551.4 million in cash and other financial assets.
Immatics NV (NASDAQ:IMTX) is a German clinical-stage biopharmaceutical company. It focuses on developing treatments for cancer patients. The lead drug candidate, Enzo Cell (IMA203), targets certain types of melanoma.
While we accept the potential of IMTX as an investment, we believe that some AI stocks offer more potential and lower risk. If you’re looking for the most undervalued AI stocks that stand to benefit significantly from Trump-era tariffs and the offshore trend, check out our free report Best short-term AI stocks.
Read more: 12 Top Consumer Goods Stocks Billionaires Are Quietly Buying And Goldman Sachs Penny Stocks: Picking the 12 Best Stocks.
Disclosure: None. Follow the inside port on Google News.
